Back to results
US 7,071,225 B2Granted
Arylaminopropane analogues and their use for the treatment of glaucoma
AssigneeAlcon Inc.
InventorsMark R. Hellberg, Abdelmoula Namil
Life of this patent
Estimating the term…
Abstract
Arylaminopropane analogues are disclosed. Also disclosed are methods for the lowering and controlling of normal or elevated intraocular pressure as well as a method for the treatment of glaucoma using compositions containing one or more of the compounds of the present invention.
Claims13
A compound represented by Formula I:
- wherein R1 and R2 are independently chosen from hydrogen or an alkyl group and R3 is C1-3 alkyl;
- R4 is H or OR1;
- R5 is OCON(R1,R2), OCOR1, or OR7;
- R6 is H, OR7, CONR1R2, CH2OR7, CO2R1R2, N(R1R2), with the proviso that both R5 and R6 are not H;
- Aryl is at least one aryl group;
- A is chosen from hydrogen, an alkyl group, C(═O)OR7, OR7, CR7, C(═O)NR1R2, SO2(NR1R2), halogen, or CF3;
- and
- R7 is H, a substituted or unsubstituted alkyl group, C1-3CONR1R2, C1-3N(R1R2), C1-3CO2H, or C1-3CO2C1-3alkyl, with the proviso that when R1, R2, and R4 each are hydrogen, R5 and R6 do not represent OR7 at the same time.
5 more elements
A pharmaceutical composition comprising the compound represented by Formula I:
- wherein R1 and R2 are independently chosen from hydrogen or an alkyl group and R3 is C1-3 alkyl:
- R4 is H or OR1;
- R5 is OCON(R1,R2), OCOR1, or OR7;
- R6 is H, OR7, CONR1R2, CH2OR7, CO2R1R2, N(R1R2), with the proviso that both R5 and R6 are not H;
- Aryl is at least one aryl group;
- A is chosen from hydrogen, an alkyl group, C(═O)OR7, OR7, CR7, C(═O)NR1R2, SO2(NR1R2), halogen, or CF3;
- and
- R7 is H, a substituted or unsubstituted alkyl group, C1-3CONR1R2, C1-3N(R1R2), C1-3CO2H, or C1-3CO2C1-3alkyl, and at least one ophthalmologically acceptable carrier.
5 more elements
Dependencies are inferred from the claim text.